Danaher stock steadies on 2025 revenue and earnings

Danaher Corp. (ISIN US2358511028) stock is anchored by its 2025 numbers: revenue was $24.4 billion, adjusted diluted net earnings per share were $7.70, and free cash flow reached $5.4 billion. Those figures frame the company ahead of its next reporting cycle and give investors a concrete baseline for 2026 comparisons.

Revenue at $24.4 billion

In 2025, Danaher reported $24.4 billion in revenue, according to its annual report. That result matters because it gives a full-year scale reference rather than a single-quarter snapshot, and it is the cleanest market-relevance anchor available for the stock today.

Adjusted diluted net earnings per share of $7.70 in 2025 show how the company converted that revenue into bottom-line profit. Free cash flow of $5.4 billion in the same year adds another layer, because cash generation is often where a life-sciences and diagnostics group is judged most closely.

Cash flow stayed high

Danaher’s $5.4 billion in free cash flow for 2025 gives a second dated metric with clear investor relevance. The gap between revenue and cash flow is also meaningful: a business producing more than $24 billion in sales and $5 billion-plus in free cash flow has room to fund research, bolt-on acquisitions, and shareholder returns.

The comparison that stands out is the earnings mix: revenue of $24.4 billion and adjusted EPS of $7.70 in 2025 show the scale of the operating base, while the free-cash-flow conversion of $5.4 billion provides a concrete reference for margin quality. For a diversified health-care supplier, that combination is more informative than a headline price move alone.

Diagnostics and biotech

Danaher’s product mix is still centered on diagnostics, life sciences, and biotechnology tools, which are the business lines that typically drive recurring demand and recurring service revenue. The company’s portfolio includes instruments, consumables, and related services used across research, clinical, and industrial settings.

That mix is important because it explains why the 2025 revenue and cash-flow base can matter to the stock even without a fresh event headline. Investors usually read the annual numbers as a check on demand stability, execution, and the durability of margins.

Stock around the latest base

The share-price line is omitted here because no dated market quote is available in this call, so the article uses the latest evidenced financial baseline instead. Danaher stock remains tied to the 2025 operating figures until the next report updates the picture.